JP2008005838A - 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法 - Google Patents
新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法 Download PDFInfo
- Publication number
- JP2008005838A JP2008005838A JP2007146291A JP2007146291A JP2008005838A JP 2008005838 A JP2008005838 A JP 2008005838A JP 2007146291 A JP2007146291 A JP 2007146291A JP 2007146291 A JP2007146291 A JP 2007146291A JP 2008005838 A JP2008005838 A JP 2008005838A
- Authority
- JP
- Japan
- Prior art keywords
- peroxidase
- detection
- sample
- activity
- reagent composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108040007629 peroxidase activity proteins Proteins 0.000 title claims abstract description 197
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 26
- 102000003992 Peroxidases Human genes 0.000 title abstract description 189
- 208000027866 inflammatory disease Diseases 0.000 title abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 85
- 210000003296 saliva Anatomy 0.000 claims abstract description 80
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 210000000214 mouth Anatomy 0.000 claims abstract description 14
- 229960001867 guaiacol Drugs 0.000 claims abstract description 9
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 68
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 68
- 210000002966 serum Anatomy 0.000 claims description 29
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 24
- 229960000860 dapsone Drugs 0.000 claims description 21
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 19
- 102000045576 Lactoperoxidases Human genes 0.000 claims description 19
- 229940057428 lactoperoxidase Drugs 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 238000005349 anion exchange Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000010839 body fluid Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 230000036542 oxidative stress Effects 0.000 claims description 6
- 230000003595 spectral effect Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 claims description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 claims 14
- 230000000694 effects Effects 0.000 abstract description 123
- 208000028169 periodontal disease Diseases 0.000 abstract description 30
- 206010018367 Glomerulonephritis chronic Diseases 0.000 abstract description 16
- 238000005259 measurement Methods 0.000 abstract description 15
- 230000035945 sensitivity Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract description 6
- 208000010125 myocardial infarction Diseases 0.000 abstract description 6
- 206010013781 dry mouth Diseases 0.000 abstract description 5
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 239000011345 viscous material Substances 0.000 abstract description 2
- 239000011343 solid material Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 118
- 238000006243 chemical reaction Methods 0.000 description 35
- 206010003210 Arteriosclerosis Diseases 0.000 description 29
- 208000011775 arteriosclerosis disease Diseases 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000011161 development Methods 0.000 description 26
- 230000018109 developmental process Effects 0.000 description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 18
- 239000000758 substrate Substances 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 201000009925 nephrosclerosis Diseases 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 102000006587 Glutathione peroxidase Human genes 0.000 description 9
- 108700016172 Glutathione peroxidases Proteins 0.000 description 9
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 238000005571 anion exchange chromatography Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WPBZMCGPFHZRHJ-UHFFFAOYSA-N 4-aminobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N)C=C1 WPBZMCGPFHZRHJ-UHFFFAOYSA-N 0.000 description 5
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 description 4
- 108700020962 Peroxidase Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003593 chromogenic compound Substances 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 101001099464 Homo sapiens Lactoperoxidase Proteins 0.000 description 3
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 3
- 102100038609 Lactoperoxidase Human genes 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 102000051251 human MPO Human genes 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000033610 salivary peroxidase Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108060006006 Cytochrome-c peroxidase Proteins 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000003433 Gingival Pocket Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010084238 NAD+ peroxidase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007146291A JP2008005838A (ja) | 2006-05-31 | 2007-05-31 | 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006150757 | 2006-05-31 | ||
| JP2007146291A JP2008005838A (ja) | 2006-05-31 | 2007-05-31 | 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008005838A true JP2008005838A (ja) | 2008-01-17 |
| JP2008005838A5 JP2008005838A5 (enExample) | 2011-01-13 |
Family
ID=39064609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007146291A Pending JP2008005838A (ja) | 2006-05-31 | 2007-05-31 | 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008005838A (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521200B2 (en) * | 2006-10-05 | 2009-04-21 | Michael Glogauer | Method for non-invasive rinse diagnosis and monitoring of periodontal diseases using colourimetric reagents |
| JP2016513795A (ja) * | 2013-03-15 | 2016-05-16 | ザ プロクター アンド ギャンブル カンパニー | 皮膚バイオマーカーから酸化的ストレス及び酸化的損傷を測定するための非侵襲的方法 |
| CN110514654A (zh) * | 2018-05-21 | 2019-11-29 | 中国农业科学院北京畜牧兽医研究所 | 一种牛乳中乳过氧化物酶的快速检测方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06130062A (ja) * | 1992-10-13 | 1994-05-13 | Godo Shiyusei Kk | ブロッキング処理を要しない、金コロイドを用いる免疫学的分析方法、およびこれに用いる分析用ストリップ |
| JPH08500342A (ja) * | 1992-07-20 | 1996-01-16 | ドューク ユニバーシティー | Ｈｉｖ複製を阻害する化合物 |
| JPH0954086A (ja) * | 1995-08-10 | 1997-02-25 | Kdk Corp | ヘモグロビン▲ａ１ｃ▼測定用試験片 |
| JPH09113514A (ja) * | 1995-10-20 | 1997-05-02 | Kdk Corp | グリコアルブミン測定用乾式試験具 |
| WO1999043846A1 (en) * | 1998-02-25 | 1999-09-02 | Ehud Keinan | Method and kit for the detection of explosives |
| JP2004267067A (ja) * | 2003-03-06 | 2004-09-30 | Osaka Industrial Promotion Organization | アルコール分析方法 |
-
2007
- 2007-05-31 JP JP2007146291A patent/JP2008005838A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08500342A (ja) * | 1992-07-20 | 1996-01-16 | ドューク ユニバーシティー | Ｈｉｖ複製を阻害する化合物 |
| JPH06130062A (ja) * | 1992-10-13 | 1994-05-13 | Godo Shiyusei Kk | ブロッキング処理を要しない、金コロイドを用いる免疫学的分析方法、およびこれに用いる分析用ストリップ |
| JPH0954086A (ja) * | 1995-08-10 | 1997-02-25 | Kdk Corp | ヘモグロビン▲ａ１ｃ▼測定用試験片 |
| JPH09113514A (ja) * | 1995-10-20 | 1997-05-02 | Kdk Corp | グリコアルブミン測定用乾式試験具 |
| WO1999043846A1 (en) * | 1998-02-25 | 1999-09-02 | Ehud Keinan | Method and kit for the detection of explosives |
| JP2004267067A (ja) * | 2003-03-06 | 2004-09-30 | Osaka Industrial Promotion Organization | アルコール分析方法 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012044474; Ｊ． Ｅｘｐ． Ｂｏｔ． （２００２） ｖｏｌ．５３， ｎｏ．３６７， ｐ．３０３-３１１ * |
| JPN6012044476; Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｍｏｓｃ． （１９９７） ｖｏｌ．６２， ｎｏ．８， ｐ．８７０-８７１ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521200B2 (en) * | 2006-10-05 | 2009-04-21 | Michael Glogauer | Method for non-invasive rinse diagnosis and monitoring of periodontal diseases using colourimetric reagents |
| JP2016513795A (ja) * | 2013-03-15 | 2016-05-16 | ザ プロクター アンド ギャンブル カンパニー | 皮膚バイオマーカーから酸化的ストレス及び酸化的損傷を測定するための非侵襲的方法 |
| CN110514654A (zh) * | 2018-05-21 | 2019-11-29 | 中国农业科学院北京畜牧兽医研究所 | 一种牛乳中乳过氧化物酶的快速检测方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghayour-Mobarhan et al. | Determinants of serum copper, zinc and selenium in healthy subjects | |
| Verde et al. | Use of N, N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma | |
| KR101958699B1 (ko) | 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램 | |
| Chen et al. | Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? | |
| Matsumoto et al. | Relationship between plasma D-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation | |
| Mirzaii‐Dizgah et al. | Salivary high‐sensitivity cardiac troponin T levels in patients with acute myocardial infarction | |
| Samadi et al. | Oxysterol species: reliable markers of oxidative stress in diabetes mellitus | |
| Condezo-Hoyos et al. | A plasma oxidative stress global index in early stages of chronic venous insufficiency | |
| IE911975A1 (en) | Antioxidant assay | |
| Rajapurkar et al. | Association of catalytic iron with cardiovascular disease | |
| Khaira et al. | Antioxidant consumption during exercise in intermittent claudication | |
| Masudo et al. | Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood | |
| GB2250819A (en) | Myocardial infarction test | |
| JP4820192B2 (ja) | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 | |
| Ozdemir et al. | An evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic nephropathy | |
| JP2002181815A (ja) | 唾液成分の免疫学的測定法 | |
| KR20190088181A (ko) | 뇌졸중 진단 또는 예후예측용 바이오마커 및 이의 용도 | |
| MacCallum et al. | Sex differences in the determinants of fibrinolytic activity | |
| WO2013016425A2 (en) | Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease | |
| JP2009145220A (ja) | 歯周病の診断方法及び歯周病診断キット | |
| Boaz et al. | Baseline oxysterols and other markers of oxidative stress, inflammation and malnutrition in the vitamin e and intima media thickness progression in end-stage renal disease (VIPER) cohort | |
| US6261796B1 (en) | Method and kit for measuring mitochondrial activity | |
| Burns et al. | Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease | |
| JP7092565B2 (ja) | 好中球細胞の活性を評価する方法 | |
| Farriol et al. | Antioxidant capacity in severely burned patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100504 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100504 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121027 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121102 |
|
| A59 | Written plea |
Free format text: JAPANESE INTERMEDIATE CODE: A59 Effective date: 20130101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130103 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130531 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20130730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140218 |